1. Introduction {#sec1-viruses-11-01007}
===============

Influenza A virus (IAV), a member of the Orthomyxoviridae family, is a negative-sense, single-stranded, enveloped, segmented RNA virus \[[@B1-viruses-11-01007],[@B2-viruses-11-01007]\]. IAV usually infects epithelial cells of the upper and lower respiratory tracts, including the nasal mucosa, trachea, and lungs, with no evident symptoms during the early phase of infection \[[@B3-viruses-11-01007],[@B4-viruses-11-01007]\]. Once an influenza virus invasion occurs, innate immunity is activated, and interferons are secreted by host cells to limit the early viral proliferation \[[@B3-viruses-11-01007]\]. Then, adaptive immunity is activated by other cytokines produced during viral infection. However, in some cases, highly pathogenic influenza viruses induce cytokine storms, a consequence of excessive production of cytokines and interferon, resulting in infections and even death \[[@B5-viruses-11-01007]\].

To facilitate virus replication in the host cells, IAV has evolved strategies to block the innate and adaptive immune responses of the host cells and seize organelles from host cells to synthesize a large number of metabolites required for viral reproduction, as well as energy for the packaging of the virus \[[@B6-viruses-11-01007],[@B7-viruses-11-01007]\]. Enveloped, non-enveloped, DNA and RNA viruses share lipid metabolites in their replication cycles to induce the formation of new cytoplasmic membrane structures, which contribute to the replication and packaging of the viral genome \[[@B8-viruses-11-01007],[@B9-viruses-11-01007],[@B10-viruses-11-01007]\]. Lipid metabolism also can block the innate immune response of host cells to ensure the large-scale replication of the virus. Therefore, IAV infection is linked closely to metabolism, and the proliferation of the virus also is inseparable from the host metabolism. This changing trend in small molecule metabolites may serve as a characterization of host--pathogen interactions to monitor immune status.

Although significant progress has been made toward an anti-influenza virus drug discovery, including M2 ion channel blockers, neuraminidase inhibitors, and polymerase inhibitors \[[@B11-viruses-11-01007]\], challenges posed by drug toxicity and viruses with genetic resistance remain a serious problem \[[@B12-viruses-11-01007],[@B13-viruses-11-01007],[@B14-viruses-11-01007],[@B15-viruses-11-01007]\]. Previous research demonstrated the metabolic effects of influenza virus infection in Madin--Darby canine kidney (MDCK) cells, displaying the intra- and extra-cellular metabolite profiling upon IAV infection \[[@B16-viruses-11-01007],[@B17-viruses-11-01007]\]. Little is known, however, about the systemic metabolic dynamics during the early stage of virus infection. During our study, we analyze changes in metabolism upon influenza virus infection in human cells during the first infectious cycle via metabolomics. Early metabolite analysis will throw new light on the activation of the innate immune metabolism. We believe that the results of this work will elucidate the activation of innate immunity to viral infection from the perspective of the host and provide new control strategies for the development of novel drugs and the treatment and prevention of influenza virus infection.

2. Materials and Methods {#sec2-viruses-11-01007}
========================

2.1. Cell Culture and Viral Preparation {#sec2dot1-viruses-11-01007}
---------------------------------------

Human lung carcinoma epithelial cells (A549), MDCK cells and mouse lung epithelium (MLE-12) cells were grown in Dulbecco's modified Eagle's medium (DMEM; Gibco) supplemented with 10% fetal bovine serum (FBS, Gibco) in 5% CO~2~ at 37 °C. The IAV A/WSN/33 (H1N1) was propagated at 37 °C for 72 h in allantoic cavity-specific pathogen-free embryonated eggs at 10 days of age. Virus titers were determined by a plaque assay. Virus stocks were stored at −80 °C until use.

2.2. Plaque Assay {#sec2dot2-viruses-11-01007}
-----------------

MDCK cells were seeded in 12-well plates, infected with serial dilutions of the virus in serum-free DMEM supplemented with 4 μg/mL of [l]{.smallcaps}-1-tosylamido-2-phenyethyl chloromethyl ketone (TPCK)-treated trypsin for 2 h, and then washed with phosphate-buffered saline (PBS). The cells were covered with Modified Eagle's Medium containing 1% agarose (AMRESCO) and 2 μg/mL of TPCK-treated trypsin. The plates were allowed to solidify at 4 °C for 5 min and incubated upside-down at 37 °C. Following 72 h, viral titers were determined by counting the visible plaques.

2.3. Virus Infection In Vitro and In Vivo {#sec2dot3-viruses-11-01007}
-----------------------------------------

When the A549 cells reached high confluence (\>95%), they then were cultured for 4 h in serum-free DMEM, compared with controls under identical culture conditions, and infected with WSN at a multiplicity of infection (MOI) of 0.1, 1, and 5. The virus inoculums were removed by washing with PBS and incubation in DMEM for the indicated times in 5% CO~2~ at 37 °C. The infected cells were collected at 0 h, 8 h, and 16 h and stored at −80 °C.

The A/WSN/33 (H1N1) virus titer was determined by plaque assays. Groups of six 6--8-week-old female BALB/c mice were intranasally inoculated with 50 μL of 5000 p.f.u of virus diluted in phosphate-buffered saline (PBS). Mock-infected control animals were inoculated intranasally with 50 μL PBS. Animals that showed signs of severe disease and weight loss \>30% of their initial body weight were considered moribund and were sacrificed humanely according to animal ethics guidelines. Five mice from each group were euthanized at 0 h, 12 h, 24 h, and 48 h and necropsies were performed. The lung tissue samples were homogenized in PBS with antibiotics in a homogenizer and used to determine the viral titers using the plaque assay. The lung tissue and serum were divided into three portions, used for an enzyme-linked immunosorbent assay (ELISA) and a metabolite concentration test, respectively.

2.4. Immunofluorescence Assay {#sec2dot4-viruses-11-01007}
-----------------------------

Cells were cultured overnight in 24-well plates. Prior to the assays, cells were cultured for 4 h in a serum-free medium and then infected with WSN at a MOI of 0.1. Cells (500 μL) were collected at 0 h, 2 h, 5 h, and 8 h, washed with PBST, fixed in 4% paraformaldehyde, and stored at 4 °C overnight. Samples then were blocked with 4% bovine serum albumin (BSA) and stained with anti-influenza A virus nucleoprotein (NP) antibody (1:500). The secondary antibody (1:200) was fluorescein isothiocyanate (FITC) -conjugated goat anti-rabbit IgG, followed by 4′,6-diamidino-2-phenylindole (DAPI) staining for 15 min. Samples then were observed using a model Leica SP8 confocal laser scanning ﬂuorescence microscope (Olympus). A549 cells and MDCK cells also were collected at 0 h, 12 h, 16 h, and 24 h, and infected with WSN at a 0.1, 1, and 5 MOI ([Figure S1](#app1-viruses-11-01007){ref-type="app"}).

2.5. Sample Preparation, ELISA, and Metabolomics Analysis {#sec2dot5-viruses-11-01007}
---------------------------------------------------------

The cells were washed twice with pre-cooled PBS and then lysed with 1 mL of methanol/acetonitrile/water (2:2:1, *v*/*v*) by vortexing twice for 30 min at 4 °C. The lysates then were incubated for 1 h at −20 °C, followed by centrifugation at 13,000× *g*/min for 15 min at 4 °C. The supernatants were collected and stored at --80 °C for further analysis. Metabolic concentration was determined by an ELISA assay according to the manufacturer's instruction.

2.6. Data Acquisition through LC-MS Analysis {#sec2dot6-viruses-11-01007}
--------------------------------------------

Samples were separated on an Agilent 1290 Infinity ultra-high-pressure liquid chromatography--quadrupole time-of-flight mass spectrometer (UHPLC-Q-TOF MS), with a column temperature of 25 °C, flow rate of 0.3 mL/min, and injection volume of 2 μL.

The mobile phase contained A (water, 25 mM ammonium acetate, and 25 mM ammonia) and B (acetonitrile). The gradient elution procedure was as follows: 0 min--1 min, 95% B; 1 min--14 min, decreased linearly from 95--65%; 14 min--16 min, B was decreased linearly from 65--40%; 16 min--18 min, B was maintained at 40%; 18 min--18.1 min, B was increased linearly from 40--95%; 18.1 min--23 min, B was maintained at 95%. Samples were placed in a 4 °C autosampler throughout the process. To avoid the effects of instrument detection signal fluctuations, continuous analysis of samples was performed in random order. QC samples were inserted into the sample queue to monitor and evaluate the stability of the system and the reliability of the experimental data.

The electrospray ionization (ESI) positive and negative ion modes were used for mass spectrometer (MS) detection. The samples were separated by ultra-high-pressure liquid chromatography (UHPLC) and subjected to MS using a Triple TOF 5600 mass spectrometer (ABSCIEX). The ESI source conditions were as follows: Ion Source Gas1 (Gas1): 60, Ion Source Gas2 (Gas2): 60, Curtain gas (CUR): 30, source temperature: 600 °C, IonSapary Voltage Floating (ISVF) range −5500 V to 5500 V; TOF MS scan m/z range: 60 Da--1000 Da, production scan m/z range: 25 Da--1000 Da, TOF MS scan accumulation time 0.2 s/spectra, production scan accumulation time 0.05 s/spectra; Information Dependent Acquisition (IDA) was obtained and adopted high sensitivity mode, Declustering potential (DP) range −60 V to 60 V; Collision Energy range 20 eV to 50 eV; IDA was set to exclude isotopes with 4 Da, candidate ions to monitor per cycle 6.

2.7. Statistical Analysis {#sec2dot7-viruses-11-01007}
-------------------------

XCMS software (<https://xcmsonline.scripps.edu/index.php>) was used to analyze the raw data for peak alignment, calibration, and retention time peak area extraction. Metabolite structure identification used a method of accurate mass matching (\<25 ppm). Ion peaks with missing values \>50% in the data group were deleted. SIMCA-P 14.1 (Umetrics, Umea, Sweden) was used to establish a statistical model \[[@B18-viruses-11-01007]\]. The data were preprocessed by Pareto-scaling for multidimensional statistical analysis, including unsupervised principal component analysis (PCA) \[[@B19-viruses-11-01007],[@B20-viruses-11-01007]\], supervised partial least squares discriminant analysis (PLS-DA) \[[@B21-viruses-11-01007]\], and orthogonal partial least squares discriminant analysis (OPLS-DA) \[[@B22-viruses-11-01007]\]. Single-dimensional statistical analysis included Student's *t*-test and variation multiple analyses, and the PCA maps, volcano maps, and cluster maps were generated with the R program.

2.8. Differential Metabolite Analysis and Functional Pathway Analysis {#sec2dot8-viruses-11-01007}
---------------------------------------------------------------------

Via the Variable Importance for the Projection (VIP), the characteristics of metabolite expression patterns were used to mine the differential metabolites with biological significance. During our study, VIP \>1 was selected as the screening standard, and the differences between the groups initially were screened. Univariate statistical analysis was used to confirm significant differences in metabolites. Differential metabolites were identified by adjustments of the *p*-value for multiple testing at both VIP \>1 and univariate statistical analysis *p* \< 0.05.

To identify the altered metabolic pathways involved during influenza virus infection, the differential metabolites were subjected to the statistical tool MetaboAnalyst 4.0 ([www.metaboanalyst.ca](www.metaboanalyst.ca)), which is a web-based service that provides online visual statistical analysis \[[@B23-viruses-11-01007]\]. Data were uploaded to KEGG ([www.kegg.jp](www.kegg.jp)) and HMDB 4.0 ([www.hmdb.ca](www.hmdb.ca)) for more information to identify significantly altered pathways \[[@B24-viruses-11-01007],[@B25-viruses-11-01007],[@B26-viruses-11-01007],[@B27-viruses-11-01007]\]. All these programs support a variety of complex statistical calculations and high-quality graphic rendering capabilities that require copious computing resources.

3. Results {#sec3-viruses-11-01007}
==========

3.1. Rapid Replication of IAV in the Early Stages of Infection in Human Cells {#sec3dot1-viruses-11-01007}
-----------------------------------------------------------------------------

To confirm virus replication in A549 cells, the cells were infected with A/WSN virus at a MOI of 0.1, and virus replication was analyzed. The ratio of infected cells also was identified by measuring viral intracellular NP using immunofluorescence microscopy analysis. We found that the number of infected cells at 8 h was greater than that of cells infected at 2 h and 5 h ([Figure 1](#viruses-11-01007-f001){ref-type="fig"}A), and that virus titers in the A549 cell progressively increased until reaching a peak at 24 h post-infection, indicating more efficient virus replication within 24 h post-infection ([Figure 1](#viruses-11-01007-f001){ref-type="fig"}B). Consistent results were observed in A549 cells infected with A/WSN/1933 and analyzed at different time points, and the virus production was comparable in a single-cycle infection, while infected cells at a MOI of 1 or 5 displayed a higher cell death ([Figure S1](#app1-viruses-11-01007){ref-type="app"}).

3.2. Characteristic Metabolites in Response to Virus Infection {#sec3dot2-viruses-11-01007}
--------------------------------------------------------------

Metabolite isolates were prepared individually from both WSN virus- and mock-infected A549 cells. To identify the functions of the characteristic metabolites during viral infection, univariate analysis was performed to analyze the total metabolite profiles in uninfected or WSN-infected A549 cells. Volcano plots in [Figure S2](#app1-viruses-11-01007){ref-type="app"} show all differentially expressed metabolites were identified. The variations in metabolites were correlated with different time points, and changes in up-regulated metabolites were more abundant at 2 h post-infection, while the down-regulation of metabolites was more significant at 8 h post-infection ([Figure 2](#viruses-11-01007-f002){ref-type="fig"}A).

To compare metabolite expression profiles at 2 h, 5 h, and 8 h post-infection, we filtered metabolites with fold analysis, calculating the 50 differentially expressed metabolites ([Table 1](#viruses-11-01007-t001){ref-type="table"}). Shown in the heat map diagrams in [Figure 2](#viruses-11-01007-f002){ref-type="fig"}B--D, we depict the upregulated and downregulated metabolites in A549 cells responding to WSN virus infection induced at different time points, indicating the various metabolic influences induced by virus infection.

3.3. KEGG Pathway Enrichment Analyses Based on Metabolites {#sec3dot3-viruses-11-01007}
----------------------------------------------------------

To identify the biological interactions of metabolites and determine important functional networks upon WSN infection in human cells, we analyzed the statistically enriched metabolites, listing the top 20-fold changes by the absolute value of the log~2~ scale obtained from the A549 cell lines ([Figure 3](#viruses-11-01007-f003){ref-type="fig"}A); we mapped the metabolites with altered expression into their KEGG pathways. We present the results of the top 30 pathways activated by the WSN virus in A549 cells in [Table 2](#viruses-11-01007-t002){ref-type="table"}. Upon WSN virus infection, the most significantly activated cellular metabolite process was purine metabolization.

We also mapped metabolites identified at individual time points into the KEGG pathway database to further explain the individual function analysis. The top 15 enriched pathways in WSN-infected A549 cells are summarized in [Figure 3](#viruses-11-01007-f003){ref-type="fig"}. Two hours post-infection, ABC transporters and the FoxO signaling pathway, which are in the biological process category, were regulated most significantly by WSN infection (*Q* \< 0.05 and *p* \<0.01) ([Figure 3](#viruses-11-01007-f003){ref-type="fig"}B). During the next 6 h, choline metabolization in cancer and taurine, and hypotaurine metabolization were associated highly with the responses to WSN infection in A549 cells ([Figure 3](#viruses-11-01007-f003){ref-type="fig"}B,C).

3.4. Metabolite Correlation Network Diagram Analysis {#sec3dot4-viruses-11-01007}
----------------------------------------------------

We also used MetaboAnalyst 4.0 analyses to reveal the possible functions of the identified unique metabolites in cell samples. Examining the differential unique metabolites in the WSN group relative to glutathione metabolization and purine metabolization in A549 cells, we found the most enriched biological processes to be related mainly to the TCA cycle, arachidonic acid metabolization, and the hexosamine pathway ([Figure 4](#viruses-11-01007-f004){ref-type="fig"}), with purine metabolization and fatty acid biosynthesis as the most significant molecular functions.

3.5. Trends in Key Metabolites by Box Plots of Different Times by Infection {#sec3dot5-viruses-11-01007}
---------------------------------------------------------------------------

By assembling box plots of selected metabolites across our experimental time, the differential expression profiles of the metabolites were validated. Although minor differences were observed in the different times due to their intrinsic differences, the results of these analyses demonstrated the key relative regulation of metabolites ([Figures S3--S5](#app1-viruses-11-01007){ref-type="app"}).

The common regulative metabolites (PGH, O-acetylcholine, and hypoxanthine) induced by WSN infections are linked to elevated morbidity and mortality in humans \[[@B28-viruses-11-01007]\]. [Figure 5](#viruses-11-01007-f005){ref-type="fig"}A shows the expression of the most regulative metabolites differed in infected A549 cells between 2 h post-infection and the next 6 h. However, the levels of PGH and O-acetylcholine, as well as hypoxanthine, were decreased markedly in WSN-infected A549 cells at 5 h post-infection. These findings suggest a remarkable initiation of the response of the host metabolic levels and capacity in WSN-infected A549 cells. To further confirm these results in vivo mice were intranasally inoculated with 50 μL of 5000 p.f.u of virus or PBS as a negative control. The lung tissue homogenates and serum samples were detected using an ELISA assay. Consistent results were observed in PGH2 and hypoxanthine expression. According to the metabolomic analysis data, acetylcholine displayed similar expression in the lung tissue, while the expression in serum was not changed significantly ([Figure 5](#viruses-11-01007-f005){ref-type="fig"}A). Additionally, we observed similar results in mouse lung epithelium (MLE-12) cells ([Figure S6](#app1-viruses-11-01007){ref-type="app"}). The viral lung titers of the mice infected with WSN also are displayed in [Figure S7](#app1-viruses-11-01007){ref-type="app"}.

4. Discussion {#sec4-viruses-11-01007}
=============

Influenza virus infection is linked inextricably to metabolism, and the proliferation of the virus is inseparable from the host metabolism. The mouse-adapted WSN virus, which is recognized as a neurovirulent strain, also can cause severe lung hypoxemia and pulmonary edema in mice \[[@B29-viruses-11-01007]\]. Previous research demonstrated that blunting the cytokine storm significantly alleviated the syndrome of animals infected with WSN virus \[[@B5-viruses-11-01007],[@B30-viruses-11-01007]\]. Though the prospect of blunting over-abundant innate immune response is enticing, little is known about the activation of an innate immune metabolism during early virus infection and the potential metabolites modulating immune response and virus replication. During our study, we identified \>50 differential metabolites by exploring the metabolism and metabolic characteristics of early viral infection, established through the integration of statistical analyses and metabolic networks. Host metabolic changes upon influenza virus infection play a key role in regulating virus replication.

Influenza viruses can utilize the host's energy metabolism for their own replication. Our study found no significant changes in intermediate metabolites in the TCA cycle during the first replication cycle (prior to 8 h). We conclude that the enzyme in the TCA cycle is still active. We observed the same phenomenon in the TCA cycle in the PR8-infected MDCK cell model over the first 10 h \[[@B16-viruses-11-01007]\]. The IAV usually leads to apoptosis, which is caused by damage to the mitochondrial membrane after infection \[[@B31-viruses-11-01007]\]. Apoptosis leads to more severe metabolic disorders, destroying cellular respiration. Apoptosis-related gene transcription levels were downregulated within 8 h prior to WSN infection \[[@B32-viruses-11-01007]\]. Therefore, we believe that mitochondria remain intact in morphology and function during the first replication cycle of an influenza virus, and no apoptosis occurs. Concurrently, an increase in glutamate content was observed in glutathione metabolization, a strategy in which cells maintain high levels of oxidized coenzymes under high pressure to maintain an energy metabolism balance. During the first replication cycle, the mitochondrial energy supply is maintained by up-regulating the glutamate content to maintain TCA cycle stability to complete viral replication.

Theoretically, even if all a metabolite were disappeared in infected cells, expression of the metabolite would become 80--90% in this MOI 0.1 condition. However, our data shows that many metabolites were down-regulated several times, while our speculation was related to the regulation of uninfected cells by infected cells. Previous studies have found that virus infection between cells is a spatial process, depending on where the virus is at the infection time point. Infected cells gradually activate the antiviral immunity of surrounding uninfected cells through cytokines such as interferon \[[@B33-viruses-11-01007],[@B34-viruses-11-01007],[@B35-viruses-11-01007]\]. Our study concentrated on the first cycle of virus replication, there was no progeny virus production. Therefore, we speculated that the infected cells, centered on the infected cells, communicated with the surrounding signals and produced the same metabolic changes, instructing the uninfected cells to enter the antiviral state, thus leading to such changes in metabolites.

We also found the negative regulatory effect of influenza virus on the metabolic pathway for fatty acids. According to our data, the relative abundance of myristic acid, palmitic acid, palmitoleic acid, and oleic acid was decreased. Fatty acids have been known to play a dual role in an influenza virus metabolism \[[@B36-viruses-11-01007],[@B37-viruses-11-01007],[@B38-viruses-11-01007],[@B39-viruses-11-01007],[@B40-viruses-11-01007]\]. Previous research demonstrated the virulence of an influenza virus is enhanced by palmitoylation of the cysteine residues in the M2 protein in vivo, although this palmitoylation process is not necessary in the formation of IAV in vitro \[[@B41-viruses-11-01007]\]. Additionally, other research suggests that palmitoyl-oleoyl-phosphatidylglycerol (POPG) \[[@B42-viruses-11-01007]\], a minor component of pulmonary surfactants, effectively regulates the innate immune system. The presence of POPG significantly attenuates influenza virus-induced IL-8 production and apoptosis in human bronchial epithelial cells. During early infection, this POPG thus serves to activate the innate immune system to inhibit influenza virus replication.

Host nucleotides and their derivatives, consumed upon influenza virus replication, are important small molecules in cells involved in signal transduction \[[@B43-viruses-11-01007],[@B44-viruses-11-01007],[@B45-viruses-11-01007],[@B46-viruses-11-01007]\], energy cycling \[[@B9-viruses-11-01007],[@B47-viruses-11-01007]\] and the synthesis of genetic material \[[@B48-viruses-11-01007]\]. Li et al., demonstrated that UDP-N-acetylglucosamine was used as a substrate for the hexosamine biosynthetic pathway (HBP) to glycosylate MAVs, an important signaling adaptor protein in the innate immune signaling pathway \[[@B49-viruses-11-01007]\]. Thus, HBP plays an important role in the antiviral effect of innate immunity by targeting MAVs protein. Our results confirmed that the relative amount of UDP-*N*-acetylglucosamine increased during the first replication cycle of the virus, which may increase the glycosylation of MAVS, helping it to form prion-like aggregates to activate an antiviral response in innate immunity after viral infection. We also observed that purine metabolization changed significantly during the first cycle. Purine plays an important role in the biological processes of cells \[[@B50-viruses-11-01007],[@B51-viruses-11-01007]\], Chandler et al., reported lung tissue was taken for metabolomics analysis at 10 days by IAV infection to obtain a decrease in AMP content; our data further enhances previous research that AMP content increased within 2 h by the first cycle of viral replication \[[@B52-viruses-11-01007]\]. This may indicate that AMP plays an irreplaceable role as a core component in the metabolism of purine \[[@B53-viruses-11-01007]\]. A sharp increase in AMP may increase the ratio of ATP/AMP, thereby activating the AMPK pathway \[[@B54-viruses-11-01007],[@B55-viruses-11-01007],[@B56-viruses-11-01007],[@B57-viruses-11-01007]\], followed by beta-oxidation of fatty acids and glycolysis, providing more energy to the cell. The basic carbon skeleton is required for the synthesis of viruses. Here we demonstrate that influenza viruses widely use nucleotides and derivatives thereof as synthetic substrates during replication and, therefore, nucleotide starvation effectively can modulate immune responses, thereby reducing the efficiency of viral replication \[[@B58-viruses-11-01007]\].

Furthermore, prostaglandins are reported to be used by IAV to achieve immune escape. Prostaglandin H2 was upregulated in our study. PGH2 is the first intermediate in the biosynthesis of all prostaglandins, which can be converted into PGE2 and PGD2 with biological activity \[[@B59-viruses-11-01007],[@B60-viruses-11-01007]\]. PGE2 is expressed in macrophages during influenza infection, and inhibiting PGE2 can promote the aggregation of macrophages into the lungs and produce interferon \[[@B59-viruses-11-01007]\]. However, to expand the infection of the influenza virus, DC cell migration is inhibited by PGD2 \[[@B60-viruses-11-01007]\]. Thus, the blocking of prostaglandin synthesis during early infection leads to the accelerated activation of immune cells in the lungs to suppress infection.

Taken together, the metabolic activity of the virus in the early stage of infection plays a critical role in evading the host's innate immunity and preparing a large number of substrates for its replication and proliferation. Therefore, virus infection can be targeted in the early stages of virus reproduction based on its characteristics. Accompanying the analysis of metabolomic studies, broad-spectrum antiviral drugs against post-infection lipid metabolization have been developed \[[@B8-viruses-11-01007],[@B13-viruses-11-01007]\]. This affirms that metabolomics can serve as a mature research method to regulate influenza virus infection and contribute to the prevention and treatment of influenza \[[@B55-viruses-11-01007]\].

5. Conclusions {#sec5-viruses-11-01007}
==============

To identify host cell responses to influenza-infected host cells, we used metabolomic analysis to identify differentially expressed metabolites between uninfected controls and IAV-infected A549 cells. We found that, compared to the control group, the IAV-infected group displayed a large amount of altered metabolic activity, with significant differences found in 50 discrete metabolites. These were distributed mainly in purine metabolization, lipid metabolization, and glutathione metabolization, which accelerate the replication speed of the virus for the first replication cycle of the influenza virus, but also causes innate immunity to monitor metabolic changes. To summarize, our research suggests novel approaches for the future development of immune metabolism studies and provides evidence for further confirmation of the complex regulatory mechanisms between IAV and host cells.

The following are available online at <https://www.mdpi.com/1999-4915/11/11/1007/s1>, Figure S1. Immunofluorescence staining of A549 cells post-infection with A/WSN/1933 at MOI of 0.1, 1, or 5. Figure S2. Volcano plots of metabolic changes of virus infection at different time points. Figure S3. Box plots of the 2 h metabolic changes of virus infection in A549 cells. Figure S4. Box plots of the 5 h metabolic changes of virus infection in A549 cells. Figure S5. Box plots of the 8 h metabolic changes of virus infection in A549 cells. Figure S6. The concentration of metabolites in mouse lung epithelial cells (MLE-12). (A) Metabolic changes in PGH2, (B) changes in acetylcholine metabolism, and (C) changes in hypoxanthine metabolism. Figure S7. The viral lung titers of the mice infected with WSN.
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Click here for additional data file.
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![A549 cells were infected with A/WSN/1933 at different time points. (**A**) Immunofluorescence staining of A549 cells post-infection with A/WSN/1933. Infected cells were distributed in four wells of a 24-well plate at a MOI of 0.1. The influenza virus NP protein was analyzed with FITC-conjugated antibody (left), and the nuclei were examined using DAPI staining (middle). Uninfected control is shown on the right. Scale bar, 100 μm. (**B**) Growth curve of IAVs in A549 cells. The cells were infected with A/WSN/1933 virus (MOI of 0.1). The supernatants were collected at the indicated time points, and viral titers were determined by plaque-forming units.](viruses-11-01007-g001){#viruses-11-01007-f001}

![Identification and characterization of altered metabolites after IAV infection. (**A**), Bar graph showing a large number of metabolite changes. The *X*-axis represents the time point, and the negative log~10~ of the *p*-value on the *y*-axis. The metabolites with log~2~ fold changes \>1 or \<−1 and −log~10~ *p* \> 1.3 were significantly different. Red (positive ion modes) and yellow (negative ion modes) indicate up-regulated, while dark blue (positive ion modes) and light blue (negative ion modes) indicate down-regulated. (**B**--**D**), A549 cells were infected with A/WSN/1933 viruses at a MOI of 0.1 for 2 h (**B**), 5 h (**C**), and 8 h (**D**). Total metabolites were extracted and used for metabolomic analysis. The expression values shown in shades of green and red indicate gene levels below and above the median expression value across all the samples (log~2~, from −2 to +2), respectively. Each row is a differential metabolite, and each column represents a replicate of a group.](viruses-11-01007-g002){#viruses-11-01007-f002}

![Top 15 enriched pathways based on characteristic metabolites in A/WSN/1933-infected cells. Pathway analysis allowed the construction of a scatter plot of KEGG pathway enrichment statistics for characteristic metabolites following A/WSN/1933 infection of A549 cells. (**A**) Global metabolic disorders of the most relevant pathways induced by A/WSN/1933 were revealed using MetaboAnalyst 4.0. "Pathway Impact" means that the selected metabolites conducted topological analysis of the metabolic pathway according to their different positions in the metabolic pathway. The corresponding score is shown on the *X*-axis, and the *p*-value (*Y*-axis) of the metabolic pathway enrichment analysis is selected as the most valuable metabolic pathway, (**B**--**D**). Rich factor is the ratio of the number of differentially expressed genes noted in the pathway terms to all metabolite numbers found in this pathway term. We selected the top 15 of the KEGG enrichment results as a reference. "Compound number" is the compounds here referring to the ones in [Table 1](#viruses-11-01007-t001){ref-type="table"}. A greater Rich Factor indicates higher intensity. To control the false discovery rate (FDR), we used *q* = 0.05 to correct the *p*-value of the metabolites, ranging from 0 to 1. A lower *q*-value indicates higher intensity.](viruses-11-01007-g003){#viruses-11-01007-f003}

![Schematic of metabolic pathways influenced by IAV infection. The pathways depicted here are indicative of numerous cellular metabolic pathways. Glycerophospholipid metabolism, glutathione metabolism, fatty acid biosynthesis, the hexosamine pathway, glycolysis, and purine metabolism pathways are highlighted. The metabolites with red (upregulated) and green (downregulated) labels are significantly altered metabolites in A/WSN/1933.](viruses-11-01007-g004){#viruses-11-01007-f004}

![Key metabolites by box plots of different times by infection. Metabolite concentration changes in (**A**) PGH2, (**B**) acetylcholine, (**C**) hypoxanthine, extracted from human cells, serum, and lung tissue post-infection were determined by using each peak intensity ratio. Each *p*-value is filled on the box plot with the metabolite name, and the maximum/minimum value and dispersion of the data are illustrated in GC/MS chromatograms.](viruses-11-01007-g005){#viruses-11-01007-f005}

viruses-11-01007-t001_Table 1

###### 

Summary of differentially expressed metabolites data.

  No.   Time (h)   Metabolites                               Formula                   M/Z        Mr      HMDB          PubChem    KEGG
  ----- ---------- ----------------------------------------- ------------------------- ---------- ------- ------------- ---------- --------
  1     2          1-Methylnicotinamide                      C~7~H~9~N~2~O             137.07     137.1   HMDB0000699   457        C02918
  2     2          Pantothenate                              C~9~H~17~NO~5~            218.1035   219.2   HMDB0000210   988        C00864
  3     2          Sorbitol                                  C~6~H~14~O~6~             181.0722   182.1   HMDB0000247   5780       C00794
  4     2          L-Glutamine                               C~5~H~10~N~2~O~3~         147.0754   146.1   HMDB0000641   5961       C00064
  5     2          S-Methyl-5'-thioadenosine                 C~11~H~15~N~5~O~3~S       298.0959   297.3   HMDB0001173   439176     C00170
  6                Oxidized glutathione                      C~20~H~32~N~6~O~12~S~2~   613.1575   612.6   HMDB0003337   975        C00127
  7     2          LysoPC (18:1(9Z))                         C~26~H~52~NO~7~P          522.3537   521.7   HMDB0002815   16081932   C04230
  8     2          Taurine                                   C~2~H~7~NO~3~S            126.0208   125.1   HMDB0000251   1123       C00245
  9     2          Phosphorylcholine                         C~5~H~15~NO~4~P           184.0724   184.2   HMDB0001565   1014       C00588
  10    2          Uridine diphosphate-N-acetylglucosamine   C~17~H~27~N~3~O~17~P~2~   608.087    607.4   HMDB0000290   445675     C00043
  11    2          LysoPC (16:0)                             C~24~H~50~NO~7~P          496.3379   495.6   HMDB0010382   460602     C04230
  12    2          L-Glutamic acid                           C~5~H~9~NO~4~             148.0596   147.1   HMDB0000148   33032      C00025
  13    2          Pyroglutamic acid                         C~5~H~7~NO~3~             130.0488   129.1   HMDB0000267   7405       C01879
  14    2          Niacinamide (Niacinamide)                 C~6~H~6~N~2~O             123.0541   122.1   HMDB0001406   936        C00153
  15    2          Adenosine monophosphate (AMP)             C~10~H~14~N~5~O~7~P       348.0695   347.2   HMDB0000045   6083       C00020
  16    2          Inosine                                   C~10~H~12~N~4~O~5~        269.0871   268.2   HMDB0000195   6021       C00294
  17    2          Hypoxanthine                              C~5~H~4~N~4~O             137.0446   136.1   HMDB0000157   790        C00262
  18    2          Adenine                                   C~5~H~5~N~5~              136.0609   135.1   HMDB0000034   190        C00147
  19    2          Erucamide                                 C~18~H~19~NO~4~           338.3408   313.3   HMDB0029365   5280537    C02717
  20    2          Prostaglandin H2                          C~20~H~32~O~5~            351.2177   352.5   HMDB0001381   445049     C00427
  21    2          Oxoadipic acid                            C~6~H~8~O~5~              141.0171   160.1   HMDB0000225   71         C00322
  22    2          D-Mannose                                 C~6~H~12~O~6~             179.0562   180.1   HMDB0000169   18950      C00159
  23    2          PG (16:0/18:1(9Z))                        C~40~H~77~O~10~P          747.5194   749.0   HMDB0010574   52941750   /
  24    2          Pentadecanoic acid                        C~15~H~30~O~2~            241.2175   242.4   HMDB0000826   13849      C16537
  25    5          Uridine                                   C~9~H~12~N~2~O~6~         245.0758   244.2   HMDB0000296   6029       C00299
  26    5          L-Carnitine                               C~7~H~15~NO~3~            162.1115   161.2   HMDB0000062   2724480    C00318
  27    5          Deoxyadenosine                            C~10~H~13~N~5~O~3~        252.1082   251.2   HMDB0000101   13730      C00559
  28    5          PC (16:0/16:0)                            C~40~H~80~NO~8~P          778.536    734.0   HMDB0000564   452110     C00157
  29    5          2-Hydroxyadenine                          C~5~H~5~N~5~O             152.0557   151.1   HMDB0000403   76900      /
  30    5          Uracil                                    C~4~H~4~N~2~O~2~          111.0198   112.1   HMDB0000300   1174       C00106
  31    5          MG (0:0/16:0/0:0)                         C~19~H~38~O~4~            331.2837   330.5   HMDB0011533   123409     /
  32    5          Adenosine                                 C~10~H~13~N~5~O~4~        268.1033   267.2   HMDB0000050   60961      C00212
  33    5          D-Proline                                 C~5~H~9~NO~2~             116.0694   115.1   HMDB0003411   8988       C00763
  34    5          Nicotinate (Nicotinic acid)               C~6~H~5~NO~2~             124.0383   123.1   HMDB0001488   938        C00253
  35    5          PC (18:0/18:1(9Z)) (SOPC)                 C~44~H~86~NO~8~P          832.582    788.1   HMDB0008038   24778825   C00157
  36    5          L-Acetylcarnitine                         C~9~H~17~NO~4~            204.1221   203.2   HMDB0000201   1          C02571
  37    5          Cytidine                                  C~9~H~13~N~3~O~5~         244.0919   243.2   HMDB0000089   6175       C00475
  38    5          Cytosine                                  C~4~H~5~N~3~O             112.0494   111.1   HMDB0000630   597        C00380
  39    5          Guanosine                                 C~10~H~13~N~5~O~5~        284.098    283.2   HMDB0000133   6802       C00387
  40    5          Betaine                                   C~5~H~11~NO~2~            118.0852   117.1   HMDB0000043   247        C00719
  41    8          Acetylcholine                             C~7~H~16~NO~2~            146.1164   146.2   HMDB0000895   187        C01996
  42    8          2-Ethoxyethanol                           C~4~H~10~O~2~             151.0955   90.1    HMDB0031213   8076       C14687
  43    8          Palmitoleic acid                          C~16~H~30~O~2~            253.2176   254.4   HMDB0003229   445638     C08362
  44    8          Oleic acid                                C~18~H~34~O~2~            281.2488   282.5   HMDB0000207   445639     C00712
  45    8          Arachidonic acid                          C~20~H~32~O~2~            303.2332   304.5   HMDB0001043   444899     C00219
  46    8          Myristic acid                             C~14~H~28~O~2~            227.2022   228.4   HMDB0000806   11005      C06424
  47    8          Heptadecanoic acid                        C~17~H~34~O~2~            269.2486   270.5   HMDB0002259   10465      /
  48    8          Nervonic acid                             C~24~H~46~O~2~            365.3424   366.6   HMDB0002368   5281120    C08323
  49    8          Palmitic acid                             C~16~H~32~O~2~            255.2333   256.4   HMDB0000220   985        C00249
  50    8          Acamprosate                               C~5~H~11~NO~4~S           180.0335   181.2   HMDB0014797   71158      /

viruses-11-01007-t002_Table 2

###### 

Top pathways activated by H1N1-WSN virus in A549.

  No.   Name of Pathway                               Total   Expected   Hits   −log~10~ *p*-Value
  ----- --------------------------------------------- ------- ---------- ------ --------------------
  1     Purine metabolism                             92      1.6053     8      8.9037
  2     Pyrimidine metabolism                         60      1.0469     5      5.6818
  3     Nitrogen metabolism                           39      0.68052    4      5.4648
  4     Glycerophospholipid metabolism                39      0.68052    4      5.4648
  5     Fatty acid biosynthesis                       49      0.85501    4      4.6447
  6     D-Glutamine and D-glutamate metabolism        11      0.19194    2      4.2132
  7     Glutathione metabolism                        38      0.66307    3      3.6014
  8     Nicotinate and nicotinamide metabolism        44      0.76776    3      3.2223
  9     Alanine, aspartate and glutamate metabolism   24      0.41878    2      2.7426
  10    Pantothenate and CoA biosynthesis             27      0.47113    2      2.5348
  11    beta-Alanine metabolism                       28      0.48857    2      2.4715
  12    Arachidonic acid metabolism                   62      1.0818     3      2.387
  13    Arginine and proline metabolism               77      1.3436     3      1.9036
  14    Galactose metabolism                          41      0.71541    2      1.8366
  15    Fructose and mannose metabolism               48      0.83756    2      1.5918
  16    Taurine and hypotaurine metabolism            20      0.34898    1      1.2115
  17    Aminoacyl-tRNA biosynthesis                   75      1.3087     2      0.97063
  18    Fatty acid elongation in mitochondria         27      0.47113    1      0.96782
  19    alpha-Linolenic acid metabolism               29      0.50602    1      0.91228
  20    Lysine biosynthesis                           32      0.55837    1      0.83755
  21    Amino sugar and nucleotide sugar metabolism   88      1.5355     2      0.77921
  22    Butanoate metabolism                          40      0.69796    1      0.67663
  23    Histidine metabolism                          44      0.76776    1      0.61188
  24    Primary bile acid biosynthesis                47      0.82011    1      0.56861
  25    Lysine degradation                            47      0.82011    1      0.56861
  26    Glycine, serine and threonine metabolism      48      0.83756    1      0.55507
  27    Fatty acid metabolism                         50      0.87246    1      0.52922
  28    Cysteine and methionine metabolism            56      0.97715    1      0.46024
  29    Tryptophan metabolism                         79      1.3785     1      0.27865
  30    Porphyrin and chlorophyll metabolism          104     1.8147     1      0.16712
